Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move
Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.
Read original at benzingaStocks · News reference
Skye Bioscience To Acquire Redx Pharma; Combined Company To Operate As Fibrx Therapeutics With $125M Financing
Combined company to trade on Nasdaq and operate as Fibrx Therapeutics, a fibrosis-focused company led by the Redx management team and board Company’s lead program will be RXC008, Redx’s GI-restricted pan-ROCK inhibitor
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 1:36 PM
- Checked
- Aug 14, 2026, 1:36 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Skye Bioscience Enters Into Securities Purchase Agreement With Redmile Affiliate For Aggregate Purchase Price Of Up To $22M
Entry into a Material Definitive Agreement. As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the "Company"), with the U.S. Securities and Exchange
Read original at benzinga8-K filing — Skye Bioscience, Inc. (SKYE)
Filed: 2026-08-24 AccNo: 0001628280-26-058605 Size: 801 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Read original at edgarTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Read original at benzinga